Shots:
- China’s NMPA has accepted marketing registration application for insulin degludec & liraglutide injection (IDegLira), developed by TUL’s wholly owned subsidiary Zhuhai United Bio-Pharmaceutical
- IDegLira is a once-daily fixed-dose combination of basal insulin degludec and the GLP-1 analogue liraglutide for type 2 diabetes, designed to provide complementary glucose-lowering effects while simplifying treatment
- Through complementary and synergistic mechanisms, the combination overcomes monotx. limitations, providing stable 24hr. glycemic control, improving glycemic target attainment, and addressing weight management & hypoglycemia risk
Ref: The United Laboratories | Image: The United Laboratories | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
